APA

Porter C., Armstrong-Fisher S., Kopotsha T., Smith B., Baker T., Kevorkian L. & Nesbitt A. (20171204). Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. : Journal of reproductive immunology.

Chicago

Porter Charlene, Armstrong-Fisher Sylvia, Kopotsha Tim, Smith Bryan, Baker Terry, Kevorkian Lara and Nesbitt Andrew. 20171204. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. : Journal of reproductive immunology.

Harvard

Porter C., Armstrong-Fisher S., Kopotsha T., Smith B., Baker T., Kevorkian L. and Nesbitt A. (20171204). Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. : Journal of reproductive immunology.

MLA

Porter Charlene, Armstrong-Fisher Sylvia, Kopotsha Tim, Smith Bryan, Baker Terry, Kevorkian Lara and Nesbitt Andrew. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. : Journal of reproductive immunology. 20171204.